Published in Diabetes Technol Ther on December 22, 2014
Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care (2004) 75.82
Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ (2000) 35.06
Diabetes in Asia: epidemiology, risk factors, and pathophysiology. JAMA (2009) 11.52
The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes. Diabetologia (2003) 7.88
International clinical harmonization of glycated hemoglobin in Japan: From Japan Diabetes Society to National Glycohemoglobin Standardization Program values. J Diabetes Investig (2012) 7.33
Assessment of actual significance levels for covariate effects in NONMEM. J Pharmacokinet Pharmacodyn (2001) 4.25
Importance of shrinkage in empirical bayes estimates for diagnostics: problems and solutions. AAPS J (2009) 3.99
Leveraging prior quantitative knowledge to guide drug development decisions and regulatory science recommendations: impact of FDA pharmacometrics during 2004-2006. J Clin Pharmacol (2008) 2.22
Extensions to the visual predictive check to facilitate model performance evaluation. J Pharmacokinet Pharmacodyn (2008) 1.95
Diabetes in Japan: a review of disease burden and approaches to treatment. Diabetes Metab Res Rev (2009) 1.76
Ethnic differences in the relationship between insulin sensitivity and insulin response: a systematic review and meta-analysis. Diabetes Care (2013) 1.70
Disease system analysis: basic disease progression models in degenerative disease. Pharm Res (2005) 1.45
Pharmacokinetic/pharmacodynamic modelling in diabetes mellitus. Clin Pharmacokinet (2008) 1.44
Body composition is the main determinant for the difference in type 2 diabetes pathophysiology between Japanese and Caucasians. Diabetes Care (2013) 1.41
A mechanism-based disease progression model for comparison of long-term effects of pioglitazone, metformin and gliclazide on disease processes underlying Type 2 Diabetes Mellitus. J Pharmacokinet Pharmacodyn (2006) 1.35
Models for plasma glucose, HbA1c, and hemoglobin interrelationships in patients with type 2 diabetes following tesaglitazar treatment. Clin Pharmacol Ther (2008) 1.32
Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes. Diabetologia (2005) 1.29
Pathophysiologic approach to therapy in patients with newly diagnosed type 2 diabetes. Diabetes Care (2013) 1.19
Pharmacometrics for regulatory decision making: status and perspective. Clin Pharmacokinet (2011) 1.17
Semiparametric distributions with estimated shape parameters. Pharm Res (2009) 1.15
Relative and absolute contributions of postprandial and fasting plasma glucose to daytime hyperglycaemia and HbA(1c) in subjects with Type 2 diabetes. Diabet Med (2009) 1.09
Coefficient of failure: a methodology for examining longitudinal beta-cell function in Type 2 diabetes. Diabet Med (2002) 0.98
Fasting plasma glucose and 5-year incidence of diabetes in the JPHC diabetes study - suggestion for the threshold for impaired fasting glucose among Japanese. Endocr J (2010) 0.96
Long-term effects of pioglitazone on carotid atherosclerosis in Japanese patients with type 2 diabetes without a recent history of macrovascular morbidity. J Atheroscler Thromb (2010) 0.94
Simple pharmacometric tools for oral anti-diabetic drug development: competitive landscape for oral non-insulin therapies in type 2 diabetes. Biopharm Drug Dispos (2010) 0.93
A simple way to estimate mean plasma glucose and to identify Type 2 diabetic subjects with poor glycaemic control when a standardized HbA1c assay is not available. Diabet Med (2006) 0.92
A semi-mechanistic model of the relationship between average glucose and HbA1c in healthy and diabetic subjects. J Pharmacokinet Pharmacodyn (2013) 0.88
Long-term effects of pioglitazone in Japanese patients with type 2 diabetes without a recent history of macrovascular morbidity. Curr Med Res Opin (2009) 0.88
Is hyperglycemia a causal factor in cardiovascular disease? Does proving this relationship really matter? Yes. Diabetes Care (2009) 0.87
Glycemic control and treatment failure with pioglitazone versus glibenclamide in type 2 diabetes mellitus: a 42-month, open-label, observational, primary care study. Curr Med Res Opin (2006) 0.86
Model-based development of a PPARgamma agonist, rivoglitazone, to aid dose selection and optimize clinical trial designs. J Clin Pharmacol (2008) 0.85
A drug and disease model for lixisenatide, a GLP-1 receptor agonist in type 2 diabetes. J Clin Pharmacol (2013) 0.82
Development of a diabetes treatment simulation model: with application to assessing alternative treatment intensification strategies on survival and diabetes-related complications. Diabetes Obes Metab (2008) 0.80
A model-based approach to analyze the influence of UGT2B15 polymorphism driven pharmacokinetic differences on the pharmacodynamic response of the PPAR agonist sipoglitazar. J Clin Pharmacol (2013) 0.76
SNPs in KCNQ1 are associated with susceptibility to type 2 diabetes in East Asian and European populations. Nat Genet (2008) 8.63
Voglibose for prevention of type 2 diabetes mellitus: a randomised, double-blind trial in Japanese individuals with impaired glucose tolerance. Lancet (2009) 3.67
Association of CDKAL1, IGF2BP2, CDKN2A/B, HHEX, SLC30A8, and KCNJ11 with susceptibility to type 2 diabetes in a Japanese population. Diabetes (2007) 3.24
A genome-wide association study in the Japanese population identifies susceptibility loci for type 2 diabetes at UBE2E2 and C2CD4A-C2CD4B. Nat Genet (2010) 2.81
Genetic variations in the gene encoding ELMO1 are associated with susceptibility to diabetic nephropathy. Diabetes (2005) 2.12
Predicting the "First dose in children" of CYP3A-metabolized drugs: Evaluation of scaling approaches and insights into the CYP3A7-CYP3A4 switch at young ages. J Clin Pharmacol (2014) 1.99
Extensions to the visual predictive check to facilitate model performance evaluation. J Pharmacokinet Pharmacodyn (2008) 1.95
The role of population PK-PD modelling in paediatric clinical research. Eur J Clin Pharmacol (2010) 1.71
Population pharmacokinetics and pharmacodynamics of propofol in morbidly obese patients. Clin Pharmacokinet (2011) 1.51
Association of the gene encoding wingless-type mammary tumor virus integration-site family member 5B (WNT5B) with type 2 diabetes. Am J Hum Genet (2004) 1.49
Disease system analysis: basic disease progression models in degenerative disease. Pharm Res (2005) 1.45
A single nucleotide polymorphism within the acetyl-coenzyme A carboxylase beta gene is associated with proteinuria in patients with type 2 diabetes. PLoS Genet (2010) 1.38
The relationship between fasting hyperglycemia and insulin secretion in subjects with normal or impaired glucose tolerance. Am J Physiol Endocrinol Metab (2008) 1.37
A mechanism-based disease progression model for comparison of long-term effects of pioglitazone, metformin and gliclazide on disease processes underlying Type 2 Diabetes Mellitus. J Pharmacokinet Pharmacodyn (2006) 1.35
Morphine glucuronidation in preterm neonates, infants and children younger than 3 years. Clin Pharmacokinet (2009) 1.34
Markers of disease severity in chronic obstructive pulmonary disease. Pulm Pharmacol Ther (2005) 1.33
Genome-wide association study identifies three novel loci for type 2 diabetes. Hum Mol Genet (2013) 1.28
Polymorphisms in the 3' UTR in the neurocalcin delta gene affect mRNA stability, and confer susceptibility to diabetic nephropathy. Hum Genet (2007) 1.25
What is the right dose for children? Br J Clin Pharmacol (2010) 1.24
Association of solute carrier family 12 (sodium/chloride) member 3 with diabetic nephropathy, identified by genome-wide analyses of single nucleotide polymorphisms. Diabetes (2003) 1.23
A single-nucleotide polymorphism in ANK1 is associated with susceptibility to type 2 diabetes in Japanese populations. Hum Mol Genet (2012) 1.23
Considerations in the use of cerebrospinal fluid pharmacokinetics to predict brain target concentrations in the clinical setting: implications of the barriers between blood and brain. Clin Pharmacokinet (2002) 1.23
Genetic variations in the gene encoding TFAP2B are associated with type 2 diabetes mellitus. J Hum Genet (2005) 1.21
Comparison of the efficacy and safety of azilsartan with that of candesartan cilexetil in Japanese patients with grade I-II essential hypertension: a randomized, double-blind clinical study. Hypertens Res (2012) 1.19
Towards a mechanism-based analysis of pharmacodynamic drug-drug interactions in vivo. Pharmacol Ther (2004) 1.12
Explaining variability in tacrolimus pharmacokinetics to optimize early exposure in adult kidney transplant recipients. Ther Drug Monit (2009) 1.12
Maturation of the glomerular filtration rate in neonates, as reflected by amikacin clearance. Clin Pharmacokinet (2012) 1.10
Efficacy and safety of alogliptin in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, dose-ranging comparison with placebo, followed by a long-term extension study. Curr Med Res Opin (2011) 1.08
Association of new loci identified in European genome-wide association studies with susceptibility to type 2 diabetes in the Japanese. PLoS One (2011) 1.07
Tailor-made drug treatment for children: creation of an infrastructure for data-sharing and population PK-PD modeling. Drug Discov Today (2008) 1.07
Structural and functional analysis of pancreatic islets preserved by pioglitazone in db/db mice. Am J Physiol Endocrinol Metab (2004) 1.05
Long-term safety and efficacy of tofogliflozin, a selective inhibitor of sodium-glucose cotransporter 2, as monotherapy or in combination with other oral antidiabetic agents in Japanese patients with type 2 diabetes mellitus: multicenter, open-label, randomized controlled trials. Expert Opin Pharmacother (2014) 1.05
Allometric scaling of pharmacodynamic responses: application to 5-Ht1A receptor mediated responses from rat to man. Pharm Res (2007) 1.05
Pharmacokinetic-pharmacodynamic modeling of the antinociceptive effect of buprenorphine and fentanyl in rats: role of receptor equilibration kinetics. J Pharmacol Exp Ther (2005) 1.05
Incorporating receptor theory in mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling. Drug Metab Pharmacokinet (2009) 1.04
Markers of exacerbation severity in chronic obstructive pulmonary disease. Respir Res (2006) 1.04
Paediatric drug development: are population models predictive of pharmacokinetics across paediatric populations? Br J Clin Pharmacol (2011) 1.03
Apolipoprotein E genetic polymorphism, remnant lipoproteins, and nephropathy in type 2 diabetic patients. Am J Kidney Dis (2002) 1.02
Pharmacokinetic-pharmacodynamic modeling of the respiratory depressant effect of norbuprenorphine in rats. J Pharmacol Exp Ther (2007) 1.02
Population pharmacokinetics of paracetamol across the human age-range from (pre)term neonates, infants, children to adults. J Clin Pharmacol (2014) 1.02
Advances in paediatric pharmacokinetics. Expert Opin Drug Metab Toxicol (2010) 1.00
A neonatal amikacin covariate model can be used to predict ontogeny of other drugs eliminated through glomerular filtration in neonates. Pharm Res (2013) 1.00
Not-in-trial simulation I: Bridging cardiovascular risk from clinical trials to real-life conditions. Br J Clin Pharmacol (2013) 0.99
Individualized dosing regimens in children based on population PKPD modelling: are we ready for it? Int J Pharm (2011) 0.99
Systematic evaluation of the descriptive and predictive performance of paediatric morphine population models. Pharm Res (2010) 0.98
Evidence-based morphine dosing for postoperative neonates and infants. Clin Pharmacokinet (2014) 0.98
First dose in children: physiological insights into pharmacokinetic scaling approaches and their implications in paediatric drug development. J Pharmacokinet Pharmacodyn (2012) 0.97
Identifying the translational gap in the evaluation of drug-induced QTc interval prolongation. Br J Clin Pharmacol (2013) 0.97
Changes in GABAA receptor properties in amygdala kindled animals: in vivo studies using [11C]flumazenil and positron emission tomography. Epilepsia (2008) 0.96
Pharmacokinetics and effects of propofol 6% for short-term sedation in paediatric patients following cardiac surgery. Br J Clin Pharmacol (2002) 0.96
Body weight-dependent pharmacokinetics of busulfan in paediatric haematopoietic stem cell transplantation patients: towards individualized dosing. Clin Pharmacokinet (2012) 0.96
Mechanism-based PK-PD model for the prolactin biological system response following an acute dopamine inhibition challenge: quantitative extrapolation to humans. J Pharmacokinet Pharmacodyn (2012) 0.96
Immune reconstitution kinetics as an early predictor for mortality using various hematopoietic stem cell sources in children. Biol Blood Marrow Transplant (2012) 0.95
Pharmacokinetic-pharmacodynamic modeling of the effectiveness and safety of buprenorphine and fentanyl in rats. Pharm Res (2007) 0.95
Developmental changes in the expression and function of cytochrome P450 3A isoforms: evidence from in vitro and in vivo investigations. Clin Pharmacokinet (2013) 0.95
A bodyweight-dependent allometric exponent for scaling clearance across the human life-span. Pharm Res (2012) 0.94
Molecular mechanism by which pioglitazone preserves pancreatic beta-cells in obese diabetic mice: evidence for acute and chronic actions as a PPARgamma agonist. Am J Physiol Endocrinol Metab (2009) 0.94
Predictive performance of a recently developed population pharmacokinetic model for morphine and its metabolites in new datasets of (preterm) neonates, infants and children. Clin Pharmacokinet (2011) 0.94
Long-term effects of pioglitazone on carotid atherosclerosis in Japanese patients with type 2 diabetes without a recent history of macrovascular morbidity. J Atheroscler Thromb (2010) 0.94
Comparative population pharmacokinetics of lorazepam and midazolam during long-term continuous infusion in critically ill patients. Br J Clin Pharmacol (2004) 0.94
Pharmacometrics as a discipline is entering the "industrialization" phase: standards, automation, knowledge sharing, and training are critical for future success. J Clin Pharmacol (2010) 0.94
Allometric relationships between the pharmacokinetics of propofol in rats, children and adults. Br J Clin Pharmacol (2005) 0.94
Bone physiology, disease and treatment: towards disease system analysis in osteoporosis. Clin Pharmacokinet (2010) 0.93
Pharmacokinetics of clindamycin in pregnant women in the peripartum period. Antimicrob Agents Chemother (2010) 0.93
Naloxone reversal of buprenorphine-induced respiratory depression. Anesthesiology (2006) 0.93
Low, but physiological, concentration of GLP-1 stimulates insulin secretion independent of the cAMP-dependent protein kinase pathway. J Pharmacol Sci (2008) 0.93
Prediction of propofol clearance in children from an allometric model developed in rats, children and adults versus a 0.75 fixed-exponent allometric model. Clin Pharmacokinet (2010) 0.93
Coping with time scales in disease systems analysis: application to bone remodeling. J Pharmacokinet Pharmacodyn (2011) 0.93
Alogliptin plus voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension. Curr Med Res Opin (2011) 0.93
Pharmacokinetic-pharmacodynamic modeling of the D₂ and 5-HT (2A) receptor occupancy of risperidone and paliperidone in rats. Pharm Res (2012) 0.92
Preclinical prediction of human brain target site concentrations: considerations in extrapolating to the clinical setting. J Pharm Sci (2011) 0.92
Pilot study on the influence of liver blood flow and cardiac output on the clearance of propofol in critically ill patients. Eur J Clin Pharmacol (2007) 0.91
Systemic and direct nose-to-brain transport pharmacokinetic model for remoxipride after intravenous and intranasal administration. Drug Metab Dispos (2011) 0.91
GLP-1 stimulates insulin secretion by PKC-dependent TRPM4 and TRPM5 activation. J Clin Invest (2015) 0.91
Replication study for the association of 9 East Asian GWAS-derived loci with susceptibility to type 2 diabetes in a Japanese population. PLoS One (2013) 0.91
Drug disposition in obesity: toward evidence-based dosing. Annu Rev Pharmacol Toxicol (2014) 0.91
The impact of P-gp functionality on non-steady state relationships between CSF and brain extracellular fluid. J Pharmacokinet Pharmacodyn (2013) 0.89
Predictive performance of a busulfan pharmacokinetic model in children and young adults. Ther Drug Monit (2012) 0.89
Validation of the transferrin receptor for drug targeting to brain capillary endothelial cells in vitro. J Drug Target (2004) 0.89
Physiologically based pharmacokinetic modeling to investigate regional brain distribution kinetics in rats. AAPS J (2012) 0.88
Translation of drug effects from experimental models of neuropathic pain and analgesia to humans. Drug Discov Today (2012) 0.88
Pharmacokinetic/pharmacodynamic modelling of the EEG effects of opioids: the role of complex biophase distribution kinetics. Eur J Pharm Sci (2008) 0.88
Amoxicillin pharmacokinetics in pregnant women with preterm premature rupture of the membranes. Am J Obstet Gynecol (2007) 0.87
MIN6 is not a pure beta cell line but a mixed cell line with other pancreatic endocrine hormones. Endocr J (2008) 0.87
Online solid phase extraction with liquid chromatography-tandem mass spectrometry to analyze remoxipride in small plasma-, brain homogenate-, and brain microdialysate samples. J Chromatogr B Analyt Technol Biomed Life Sci (2010) 0.87
Developmental changes in morphine clearance across the entire paediatric age range are best described by a bodyweight-dependent exponent model. Clin Drug Investig (2013) 0.87
Pharmacokinetic-pharmacodynamic modeling of antipsychotic drugs in patients with schizophrenia Part I: the use of PANSS total score and clinical utility. Schizophr Res (2013) 0.87
Fifty-two-week long-term clinical study of luseogliflozin as monotherapy in Japanese patients with type 2 diabetes mellitus inadequately controlled with diet and exercise. Endocr J (2015) 0.86
High-performance liquid chromatography of nalbuphine, butorphanol and morphine in blood and brain microdialysate samples: application to pharmacokinetic/pharmacodynamic studies in rats. J Chromatogr B Analyt Technol Biomed Life Sci (2005) 0.86
Population pharmacokinetic and pharmacodynamic modeling of propofol for long-term sedation in critically ill patients: a comparison between propofol 6% and propofol 1%. Clin Pharmacol Ther (2002) 0.86
Pharmacokinetics and pharmacodynamics of midazolam and metabolites in nonventilated infants after craniofacial surgery. Anesthesiology (2006) 0.86